Waldron Private Wealth LLC Acquires 426 Shares of Danaher Co. (NYSE:DHR)

Waldron Private Wealth LLC boosted its position in shares of Danaher Co. (NYSE:DHR) by 10.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,369 shares of the conglomerate’s stock after purchasing an additional 426 shares during the quarter. Waldron Private Wealth LLC’s holdings in Danaher were worth $1,215,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Vanguard Group Inc. raised its stake in shares of Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after purchasing an additional 4,163,657 shares in the last quarter. Swedbank AB acquired a new stake in shares of Danaher during the 1st quarter worth $676,545,000. TD Asset Management Inc boosted its stake in Danaher by 99.0% in the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after buying an additional 675,952 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after buying an additional 563,546 shares in the last quarter. Finally, Castle Hook Partners LP acquired a new stake in shares of Danaher during the first quarter valued at about $98,913,000. 79.05% of the stock is owned by institutional investors.

Insider Activity

In related news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock worth $11,042,433 over the last ninety days. Insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of NYSE DHR traded down $10.23 during trading hours on Tuesday, hitting $261.86. 3,287,212 shares of the stock were exchanged, compared to its average volume of 2,717,444. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company’s 50 day moving average is $270.82 and its 200 day moving average is $260.34. The firm has a market capitalization of $193.96 billion, a P/E ratio of 44.23, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a one year low of $182.09 and a one year high of $281.70.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter last year, the company posted $2.05 EPS. On average, research analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is currently 18.31%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on DHR. Evercore ISI raised their price objective on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Robert W. Baird boosted their target price on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Stephens assumed coverage on Danaher in a research note on Tuesday, October 1st. They set an “overweight” rating and a $315.00 price objective on the stock. Leerink Partners increased their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Finally, Barclays lifted their price objective on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.